Developing new therapies for heart failure in older adults
A new large pre-clinical model of aging-related heart failure: a platform to develop new therapies for HFpEF
This study is looking at heart failure in older adults, especially those with kidney problems, by using young pigs to better understand the disease and find new ways to deliver treatments that can help improve heart function.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10750836 on NIH RePORTER |
What this research studies
This research focuses on heart failure with preserved ejection fraction (HFpEF), a common condition in elderly patients, particularly those with chronic kidney disease (CKD). The team has created a pre-clinical model using juvenile pigs that mimics the heart failure seen in older adults, allowing for a better understanding of the disease's progression and potential treatments. They are exploring innovative drug-delivery systems to target the heart and improve cardiac function. By studying the effects of aging and CKD on heart health, the research aims to develop new therapeutic strategies for this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those aged 65 and above, who have heart failure with preserved ejection fraction or chronic kidney disease.
Not a fit: Patients who are younger than 21 years old or do not have heart failure or chronic kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve heart function and quality of life for older adults suffering from heart failure.
How similar studies have performed: Previous research has shown promise in using similar models and drug-delivery systems for cardiac therapies, indicating potential for success in this novel approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Chade, Alejandro Roberto — University of Missouri-Columbia
- Study coordinator: Chade, Alejandro Roberto
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.